azd0530
Malignant Pleural Effusion
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Malignant Pleural Effusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin University of Washington | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Chinese PLA General Hospital | Phase 3 | BB |
Docetaxel University of Washington | Phase 2 | B |
Bortezomib National Cancer Institute (NCI) | Phase 2 | B |
Metformin University of Chicago | Phase 2 | B |
View all 19 →
Same molecule, other indications
azd0530 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →